Theresa A Sweeney

US Patent:

8513204, Aug 20, 2013

Filed:

Sep 20, 2006

Appl. No.:

11/523978

Inventors:

Richard Malcolmson - San Mateo CA, US
Alan Kugler - Montara CA, US
Theresa D. Sweeney - El Granada CA, US
Keith Washco - Fremont CA, US
Danforth Miller - San Carlos CA, US

Assignee:

Novartis AG - Basel

International Classification:

A61K 31/70

US Classification:

514 31, 536 65

Abstract:

The present invention comprises compositions and formulations comprising amphotericin B, compositions and formulations comprising amphotericin B with one or more excipients, methods of making amphotericin B compositions and formulations, as well as systems for using amphotericin B compositions and formulations. Also provided are pharmaceutical compositions comprising the formulation, methods of administering the pharmaceutical compositions and methods of treating patients with the pharmaceutical compositions.

US Patent:

20060025355, Feb 2, 2006

Filed:

Jun 21, 2005

Appl. No.:

11/158332

Inventors:

Sarma Duddu - Hyderabad, IN
Srinivas Palakodaty - Foster City CA, US
Danforth Miller - San Carlos CA, US
Alan Kugler - Montara CA, US
Christopher Frantz - Sunnyvale CA, US
Trixie Tan - Daly City CA, US
Richard Malcomson - San Mateo CA, US
Keith Washco - Fremont CA, US
Theresa Sweeney - El Granada CA, US
Thomas Tarara - Burlingame CA, US
Sarvajna Dwivedi - Redwood City CA, US
Michael Eldon - Redwood City CA, US

Assignee:

Nektar Therapeutics - San Carlos CA

International Classification:

A61K 31/7048
A61K 9/14
A61L 9/04

US Classification:

514028000, 424046000

Abstract:

A composition includes particles including at least about 95 wt % of amphotericin B, wherein the particles have a mass median diameter ranging from about 1.1 μm to about 1.9 μm. Another composition also includes particles including at least about 95 wt % of amphotericin B, wherein at least about 80 wt % of the particles have a geometric diameter ranging from about 1.1 μm to about 1.9 μm. Yet another composition includes particles including amphotericin B, wherein the particles have a mass median diameter less than about 1.9 μm, and wherein the amphotericin B has a crystallinity level of at least about 20%. Unit dosage forms, delivery systems, and methods may involve similar compositions.